- Home >
- Clinicals Trials >
- iMATRIX-Alectinib (GO42286)
Retour à la liste des essais cliniquesChildhood and adolescent cancers
iMATRIX-Alectinib (GO42286)
A Phase I/II, Open-Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Patients With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available.
- Ouvert à Paris depuis le : 10/08/2021
- Public cible : Child
- Phase : Phase I/II
Description de l'essai
This study will evaluate the safety, pharmacokinetics, and efficacy of alectinib in children and adolescents with ALK fusion-positive solid or CNS tumors for whom prior treatment has proven to be ineffective or for whom there is no satisfactory standard treatment available.
Url of the trialInvestigateur principal
